Novel Applications for Ex Vivo PDX Models of the Tumor Microenvironment

Logo
Presented by

Chris Koehler, PhD, Director of Scientific Operations at PhenoVista Biosciences

About this talk

Ex Vivo platforms not only can be used to gather additional in vivo model data throughout the in-life portion of an oncology study as well as at study completion, they also can address mechanisms of action for immuno-oncology agents and test for cytotoxicity of oncology therapeutics in an ex vivo system. In this webinar, case studies will be presented to demonstrate physiologically relevant 2D and 3D ex vivo PDX Models. Register for this webinar to learn: •How to combine physiologically relevant 2D and 3D ex vivo PDX models with quantitative fluorescence imaging and luminescence assays. •Why Use Tumor Fragments vs. Other 3D Systems? •How ex vivo PDX models more accurately reflect tumor heterogeneity and in vivo microenvironment using a tumor fragment approach. •How incorporating a diversity of readouts, including industry standard CellTiter Glo + fluorescence microscopy, can provide additional insights to drive research programs forward. •How adapting design flexibility, including drug combinations, treatment length, assay timing (3 days to 21-day assays) and readouts (RNA/Protein isolation) can improve data richness.

Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (37)
Subscribers (2403)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.